Eli Lilly has sued two pharmacies for selling unapproved products containing tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.
The new suits name Strive Pharmacy LLC and Empower Clinic Services LLC for selling unapproved drugs and making false claims about efficacy and safety.
According to Lilly, Strive’s tirzepatide which comes in standard doses added with vitamin B12 or glycine is falsely suggested to be safer and more effective than FDA-approved medicines.
Lilly said that Empower falsely suggested their efficacy by citing Lilly’s clinical studies for its compounded tirzepatide with a form of B3 added to it.
Lilly will also send about 50 cease-and-desist letters to compounding and telehealth companies, asking to confirm that they have already ceased mass compounding.
This comes months after Lilly sued medical spas for selling unapproved products containing tirzepatide.
At the time of writing, Eli Lilly and Co's stock price (NYSE: LLY) was US$804.89, with a market cap of around $763.03 billion.
